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Abstract  
Background: The prevalence of small intestine neuroendocrine tumours (SI-NETs) is increasing.  Disease 
progression is often slow and treatment options and long-term survival rates have improved, but little is 
known about health-related quality of life (HRQoL) in these patients. 
Objective: To assess HRQoL and its predictors in SI-NET patients receiving contemporary treatments. 
Methods: We measured HRQoL with 15D and SF-36 questionnaires in 134 SI-NET patients and compared 
the 15D results to those of age- and gender-standardized general population (n = 1153). In the patients, we 
studied impact of treatments, Ki67, liver metastases, circulating tumour markers, comorbidities and/or 
socioeconomic factors on HRQoL with linear regression analysis. 
Results: Mean disease duration of the patients was 81 (4-468) months, 91% had metastatic disease and 
79% received somatostatin analog treatment. Hepatic tumour load was 0% in 44.8%, <10-25% in 44.0%, 
and >25% in 11.2%, respectively. Mean fP-CgA and S-5HIAA concentrations were 15 (1.3-250) nmol/l and 
344 (24-7470) nmol/l, respectively. Overall HRQoL was significantly impaired in patients compared to 
controls (15D scores 0.864±0.105 vs 0.905±0.028, p<0.001). SI-NET patients scored worse on 9 of 15 
dimensions (sleep, excretion (ie bladder and bowel function), depression, distress, vitality, sexual activity 
(p< 0.001), breathing, usual activities, and discomfort and symptoms (p< 0.01-0.05). SF-36 scores were 
impaired and highly correlated with 15D scores (p<0.001). HRQoL was impaired in patients with (n=85) 
compared to patients without (n=49) impaired excretion (0.828 vs 0.933, p<0.001). In the patient group, 
number of medications predicted impaired HRQoL. 
Conclusions: Despite contemporary treatments, SI-NET patients have severely impaired HRQoL, including 
diarrhea, sleep, depression, vitality and sexual activity. 
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Introduction 
Small intestine neuroendocrine tumours (SI-NETs) arise from neuroendocrine cells in the jejunum or ileum 
and typically secrete bioactive peptides. Currently, increasing incidences in the range of 0.5-1.5 per 100.000 
inhabitants and year are reported [1-4]. Most tumours are grade 1 and 2, defined by a Ki67 index of ≤2% and 
2-20%, respectively [5]. They are characterized by relatively slow tumour progression and long overall survival 
[1]. Surgery is the cornerstone of treatment and advancements in systemic treatment options, including 
somatostatin analog and interferon therapy, everolimus, and peptide receptor radionuclide therapy (PRRT) 
have further improved survival rates in patients with SI-NETs. SI-NETs commonly produce serotonin and, 
when metastasized to the liver, patients may develop carcinoid syndrome including diarrhea, flushing, 
bronchospasm and, in the advanced stage, cardiac valvular fibrosis and right-sided heart failure. [6] 
Reports of improved survival rates indicate that important therapeutic goals have been achieved for this 
patient group. The somatostatin analogs octreotide and lanreotide efficiently improve symptoms of diarrhea 
and flushing.  In selected patients, debulking of liver metastases, ablative therapies and other liver-directed 
modalities may also relieve symptoms and hormonal overproduction. Quality of life is considered an 
important measure of patients' perception of the burden of their disease and the impact of treatment 
modalities. Despite this, data on health-related quality of life (HRQoL) in patients with SI-NETs are scarce.  
In this study, we compare HRQoL in a cohort of carefully characterized SI-NET patients from a single center, 
and compare the results to those of a large sample of the general population. Within the patient group, we 
searched for predictors of HRQoL. 
 
Patients and Methods 
Subjects 
Patients. Patients with a histologically confirmed diagnosis of SI-NET treated at the Division of Endocrinology 
and Department of Oncology, Helsinki University Hospital (HUH) during year 2017 were invited to participate 
in the study. Because all patients operated on for neuroendocrine tumours are referred either to the 
Endocrinology or Oncology unit at HUH. These subjects represent the majority of/all SI-NET patients in the 
HUH area. Only patients with available data on pathologic, radiologic and biochemical parameters were 
included. We identified a total of 211 subjects from our electronic patient records with the diagnosis of SI-
NET or carcinoid syndrome (ICD-codes E17.9 or E34.0). Thirty subjects were excluded from the study. Of 
them, ten had another severe disease (cognitive impairment, severe heart failure due to other cause than 
carcinoid heart, other malignancy) and two were in palliative care. Six subjects had deceased within the year. 
Clinical data was not available for twelve subjects who had been referred to our multidisciplinary NET tumour 
board for consultation. 
An invitation letter, the 15D and the SF36 questionnaires, and a supplementary questionnaire 
(Supplementary questionnaire) were sent in June 2017 to 181 patients identified from our electronic patient 
records. An additional letter was sent to all non-responders within 4-6 weeks. Biochemical and clinical 
data,comorbidities (cardiovascular disease, diabetes, depression which were taken into account if a patient 
was taking a medication for them) were retrieved from our electronic patient records. Pathology reports 
were collected from the electronic patient records. 
Control population. The results obtained with the 15D instrument were compared to those of a large age- 
and gender-standardized sample of the Finnish general population from the Finnish Health 2011 survey 
(n=1153) [7]. This sample was from the same catchment area as the patients. 
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Ethics 
The study was approved by the ethics committee of Helsinki University Hospital. All patients gave their signed 
informed consent for participation in the study. 
HRQoL Assessment 
The 15D questionnaire is a generic, standardized, well-validated, self-administered measure of HRQoL for 
persons aged 16 or more [8].  15D was chosen as it also measures the dimension of excretion, in contrast to 
SF-36, and as the results could be compared to those of a large age- and gender-standardized general 
population. The 15D proved to be the best generic HRQoL instrument regarding sensitivity and construct 
validity in a study by Richardson et al., comparing six different generic tests, including the SF-6 [9].  The 15D 
can be used both as a profile and a single score measure. The questionnaire consists of 15 dimensions: 
mobility, vision, hearing, breathing, sleeping, eating, speech, excretion (includes both bladder and bowel 
function), usual activities, mental function, discomfort and symptoms, depression, distress, vitality and sexual 
activity. Each dimension is divided into five levels and respondents choose the level best describing their 
current health status (for the 15D questionnaire, see Supplementary data). The 15D score and the 
dimensional level values (on a 0-1 scale) are calculated from the health state descriptive system by using a 
set of population-based preference or utility weights. This allows calculation of the 15D score representing 
the overall HRQoL. A higher score reflects a better HRQoL. The minimum important change for the 15D score 
is estimated to be ±0.015 and 0.015 can also be regarded as the minimum clinically important cross-sectional 
difference between groups [10].  
The SF-36 is a questionnaire measuring self-reported HRQoL in 8 dimensions: physical functioning, role 
limitations due to physical health, role limitations due to emotional problems, vitality, mental health, social 
functioning, bodily pain and general health. HRQoL scores are presented on a 0-100 scale. A higher score 
indicates better HRQoL. [11]  
In addition, the patients answered a short supplementary questionnaire (Supplementary questionnaire, see 
Supplementary data) including questions on marital status, educational level, symptoms (diarrhea, flushing, 
abdominal pain, defecation frequency) and regular medication. 
Assessment of hepatic tumour burden 
An experienced radiologist (R.L) re-assessed hepatic tumour burden of the SI-NET patients who answered 
the questionnaires employing CT (98 patients), MRI (28 patients), or 68Ga-Dotanoc PET/CT (8 patients) if no 
CT or MRI scans were available. Tumour burden was estimated using a visual semi-quantitative approach. 
This method has previously been applied in other studies on patient with NETs [12,13]: 4-6 scan slices with 
the most extensive affection were selected and scored visually for the extent of the disease. In case of 
multiple scans of the same patient, we chose the scan timely closest to the date of the HRQoL questionnaires. 
Hepatic tumour burden was divided into five categories: 0%, <10%, 10-25%, 25-50% and >50%. 
 
Laboratory Measurements 
All laboratory analyses, including serum 5-hydroxyindoleacetic acid (S-5HIAA) were performed at the Helsinki 
University Hospital Laboratory, HUSLAB, using in-house methods. Plasma chromogranin A (fP-CgA) was 
measured by radioimmunoassay. S-5HIAA was measured by liquid chromatography – mass spectrometry 
[14]. 
 
Statistical Analysis 
Statistical analysis was performed with IBM SPSS Statistics 24 for Windows. Independent samples t-test was 
used to test the statistical significance of the differences in the means between SI-NET patients and controls 
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from the general population. Independent samples t-test was also used to evaluate the impact of a single 
determinant (age, gender, educational level, use of somatostatin analog, hepatic metastases, fP-CgA level, S-
5HIAA level, PRRT, interferon, Ki67, comorbidities (cardiovascular disease, diabetes and depression), number 
of regular medications, diarrhea and flushing) on HRQoL. Linear regression analysis was used to evaluate the 
association between HRQoL and age, gender, educational level, use of somatostatin analog, S-5HIAA 
concentration, PRRT, interferon, Ki67, liver metastases, comorbidities (cardiovascular disease, diabetes) and 
number of regular medications. Correlations were analyzed with Pearson correlation coefficient. All provided 
p-values are two-sided and a p-value of <0.05 was considered statistically significant. The results are given as 
mean and standard deviation, or as percentages. 
Results 
Patient characteristics 
The response rate was 74 % with 134/181 patients answering the 15D and SF-36 questionnaires. Patient 
characteristics are given in Table 1. The mean age of the 134 respondents was 66.8±9.9 years and 55 % of 
them were women. Mean disease duration was 81±74 months. One-hundred and twenty-two patients (91%) 
had either locally advanced or metastatic disease. S-5HIAA was normal (reference range <123 nmol/l) in 69 
patients (52 %). The primary tumour had been operated in 126 patients (94 %). One-hundred and six patients 
(79 %) received somatostatin analog therapy. Thirty-six of the 134 patients had undergone PRRT. Other 
medical treatments included interferon and chemotherapy (Table 1). Eighty-five patients (63 %) suffered 
from diarrhea (3.3±2.6 times per week) and 42 patients (31 %) from flushing (2.4±3.4 times per week).  
Patients not answering the questionnaires (n=47 (26 %), age 62.7±13.4, 49% women) did not differ 
significantly from those returning the questionnaires regarding age or gender.  
Health-related quality of life in SI-NET patients compared to the general population 
15D. The mean (SD) 15D score was significantly lower in SI-NET patients compared to that of the age- and 
gender-standardized general population (0.864±0.105 vs. 0.905±0.028, p<0.001; Figure 1). This difference is 
also clinically important [10]. When comparing single dimensions, SI-NET patients had significantly impaired 
HRQoL on 9 of the 15 dimensions (excretion, sleeping, depression, distress, vitality, sexual activity (all 
p<0.001), breathing, usual activities (both p<0.01), and discomfort and symptoms (both p<0.05)). (Figure 1). 
SF-36. The mean SF-36 scores in SI-NET patients were: physical functioning 78±23, role limitations due to 
physical health 64±41, role limitations due to emotional problems 71±38, vitality 63±21, mental health 
78±17, social functioning 80±20, bodily pain 73±25 and general health 55±21. There was a significant positive 
correlation between the 15D score and the SF-36 dimension scores on all eight dimensions. The Pearson 
correlation coefficients for 15D score and SF-36 dimensions were as follows: physical functioning 0.704, role 
limitations due to physical health 0.637, role limitations due to emotional problems 0.571, vitality 0.744, 
mental health 0.665, social functioning 0.699, bodily pain 0.511 and general health 0.665, for all p<0.001. 
 
Predictors of HRQoL in SI-NET patients 
Within the patient group, only number of medications predicted impaired HRQoL in linear regression model 
(Table 2). HRQoL was not affected by the somatostatin analog in use (long-acting lanreotide vs long-acting 
octreotide, data not shown). The adjusted R square for the mean total 15D score reflecting overall HRQoL 
was 0.251. As fP-CgA and S-5HIAA correlated significantly, fP-CgA was left out from the analysis. 
Health-Related Quality of Life in Patients with and without Impaired Excretion  
Excretion, which includes both bladder and bowel function, correlated closely with self-reported diarrhea 
(r=-0.506, p<0.001). This dimension was compared in SI-NET patients with impairments (levels 2-5, 
corresponding to 15D score ≤0.8) and those with normal function (Level 1, “My bladder and bowel work 
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normally and without problems”). Clinical characteristics of SI-NET patients with and without impaired 
excretion are presented in Table 3. The mean (SD) 15D score was significantly lower in patients with impaired 
compared to normal excretion (0.828±0.103 vs. 0.933±0.067, p<0.001; Figure 2). The difference is also 
clinically important [10]. Patients with impaired excretion had a significantly higher number of defecation 
times per day (p<0.001) and more often suffered from diarrhea (p<0.001) compared to patients with normal 
excretion. Patients with impaired excretion used a significantly higher number of medications (p<0.01). 
Patients with normal excretion had higher Ki-67 proliferation index (p<0.05).  
Patients with impaired excretion also demonstrated significantly lower dimension scores in all but one SF-36  
(mental health) dimension compared to patients with normal excretion (Table 4).  
Patients with self-reported diarrhea (supplementary questionnaire) had significantly lower mean (SD) 15D 
score (0.843±0.105 vs 0.901±0.095, p<0.01) compared to patients not reporting diarrhea, and significant 
impairments in 6 of the 15 single dimensions (excretion (p<0.001); breathing and discomfort and symptoms 
(p<0.01); mobility, mental function and vitality (p<0.05)) compared to patients not reporting diarrhea. 
 
Discussion 
In the present cross-sectional study, we found that SI-NET patients are characterized by significantly impaired 
HRQoL compared to a large control population of more than 1000 persons from the same catchment area 
despite contemporary treatments. The SI-NET patients had histologically verified disease and were treated 
at a single center. This enabled us to estimate the impact of a large number of factors such as disease 
duration, treatment modalities, comorbidities, liver metastases, Ki67 proliferation index, as well as 
circulating neuroendocrine tumour markers on HRQoL. Novel findings of the present study are that the 
dimensions of excretion, sleep, depression, distress, vitality and sexual activity all are severely impaired in 
patients with SI-NETs.  
Some previous studies in patients with NETs of mixed origins also demonstrated impaired HRQoL [15-19]. A 
Norwegian study included patients with NET tumours from any part of the gastrointestinal tract (n=196) [17], 
a Swedish study defined the patients as having carcinoid tumour but included 36 patients only [16]. A large 
online anonymous survey performed in the USA reported reduced quality of life in a cohort of 663 subjects 
with self-reported diagnoses of carcinoid, islet cell or unknown underlying tumour [18]. The authors 
concluded that optimal management of NETs and carcinoid syndrome may significantly improve HRQoL 
among patients with NETs [18]. So far, only one previous study has reported equivalent HRQoL in the 
subgroup of SI-NET patients compared to a normative population [20]. However, the number of SI-NET 
patients in that study was small (n=44) and approximately 40 % of the patients were in remission. In the 
present study, 91% had local or distant metastases which may explain the lower HRQoL compared to that of 
the general population in our study.   
Approximately 60% of SI-NET patients have metastatic disease already at diagnosis [6], most commonly 
including mesenteric and para-aortic lymph nodes and the liver. In patients with SI-NETs, liver and 
retroperitoneal metastases impair prognosis and generally introduce symptoms related to hypersecretion of 
serotonin and its breakdown products, as these bioactive peptides cannot be cleared by the liver. Carcinoid 
syndrome is found in approximately 30% of SI-NET patients at diagnosis and is characterized by diarrhea, 
flushing, bronchoconstriction and fatigue. Average disease duration in the present study was 81 months and 
a majority had metastatic disease. We therefore wanted to study the impact of circulating 5HIAA 
concentrations and liver metastases on HRQoL. However, neither 5HIAA concentrations nor hepatic tumour 
burden independently predicted HRQoL in the present study.  
Diarrhea as a disease specific symptom in Si-NET was further characterized by dividing the patients in those 
with and those without impaired excretion score on 15D. Both mean SF-36 and 15D scores were significantly 
lower in patients with impaired excretion compared to patients without impaired excretion. In addition, 
mean 15D scores were significantly lower in patients with self-reported diarrhea compared to patients 
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without diarrhea. This strengthens the finding that carcinoid syndrome and, especially, diarrhea impair 
HRQoL in SI-NET patients. 
The clinical factors studied here did not clarify the cause of diarrhea. In Si-NET patients, causes of diarrhea 
are multifactorial. In addition to carcinoid syndrome, HRQoL may be related to gender, extent of bowel 
surgery, medications or other underlying diseases [21]. To our surprise, the two groups with and without 
impaired excretion did not differ with regard to age, biochemical disease control, hepatic tumour burden, or 
treatments. Neither did the two groups differ regards resection of the primary tumour (resected in the 
majority of patients, 94%). Patients with impaired excretion had a higher number of medications. The 
underlying tumour in this group was characterized by a slightly, but significantly, lower Ki-67 proliferation 
index indicating that Ki-67 does not directly correlate with hormonal hypersecretion and carcinoid syndrome 
symptoms in SI-NETs.  
The significance of the impaired excretion score and self-reported diarrhea for HRQoL in our patient group is 
somewhat surprising, as our patients receive contemporary therapy according to recent European treatment 
guidelines [22]. Altogether 79% of the patients in the present study are on somatostatin analog therapy, 
known not only to improve diarrhea and decrease fP-CgA and S-5HIAA concentrations, but also to have an 
anti-tumoural effect [12,13]. Our results imply that better treatments of diarrhea are warranted in SI-NET 
patients. Telotristat ethyl is a new drug for patients suffering from carcinoid syndrome, the current indication 
being diarrhea not adequately responding to somatostatin analog treatment [23]. Gelhorn et al and Kulke et 
al [24] reported that telotristat ethyl improves diarrhea and decreases bowel movement frequency in 
patients with carcinoid syndrome.  
In addition to impaired excretion, also depression, sleep, distress, vitality and sexuality were significantly 
impaired. Currently, as these impairments have not been acknowledged, they render little if any attention in 
the clinical follow-up and treatment of SI-NET patients. The prevalence of depression and anxiety in carcinoid 
syndrome is approximately 50% and 35%, respectively [25-27]. A case report indicated that telotristat ethyl 
in combination with a low dose selective serotonin reuptake inhibitor ameliorated diarrhea and depression 
in somatostatin analog treatment resistant carcinoid syndrome [28]. Further studies are needed to clarify 
this issue. Better treatment of depression, sleeping problems and sexual health thus seem to be other 
important targets in the management of SI-NET patients in the future. The finding of larger number of 
medications as a predictor of HRQoL in the present study may reflect symptomatic treatments of diarrhea 
and depression or other comorbidities in this subgroup.  
We also assessed the effect of PRRT, also known to improve prognosis, on HRQoL. In total, 36 of the patients 
had received PRRT. Even though PRRT is indicative of advanced and progressive disease, it did not predict or 
correlate with impaired HRQoL in our study. However, the effect of PRRT is best evaluated in a prospective 
setting. Earlier studies evaluating HRQoL in patients receiving PRRT demonstrated that this treatment 
actually improves HRQoL in NET patients [29-31] and attenuates symptoms related to the carcinoid syndrome 
[30-32]. 
We have previously used the 15D instrument when investigating HRQoL in other endocrine tumour diseases 
such as thyroid carcinoma [33], pituitary adenomas [34,35] and primary hyperparathyroidism [36]. Previous 
studies reporting impaired HRQoL in patients with NETs have utilized the SF-36 and EORTC QLQ-C30 [15-18]. 
In the present study, we used both the 15D and SF-36 and the results were highly correlated. An important 
limitation of the SF-36 is that it does not assess excretion. To the extent that the SF-36 can be regarded as a 
gold standard for measuring HRQoL in this patient group, the 15D therefore can be regarded as even better. 
The 15D is a generic, standardized and well-validated test for measuring HRQoL. Importantly, as many 
patients with SI-NETs suffer from symptoms that are common in the general population, such as depression 
and irritable bowel disease, a comparison of the findings in patients compared to a well-characterized and 
representative control population is essential. The 15D thus enabled us to compare HRQoL in SI-NET patients 
to that of a large age- and gender-standardized population. 
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An important limitation of the current study is that it is cross-sectional and observational. We could not adjust 
the 15D results of the control population for comorbidities or socioeconomic factors. Naturally, in order to 
evaluate the prognostic significance of our findings, a longitudinal prospective follow-up study on carefully 
characterized patients with SI-NETs should be performed. 
In conclusion, we demonstrate that patients with SI-NETs have severely impaired HRQoL despite 
contemporary treatments. Current treatment options have resulted in prolonged survival rates but better 
treatment of depression, diarrhea, possible disturbances in sleep and sexual activity is warranted in the 
future. 
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Appendix 
1) The 15D Questionnaire 
2) Supplementary questionnaire 
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Figure legends 
 
Fig. 1. The 15D scores and profiles of SI-NET patients (n = 134) and general population controls 
standardized for age and gender (n = 1153). Move = mobility, See = vision, Hear = hearing, Breath = 
breathing, Sleep = sleeping, Eat = eating, Excret = excretion, Uact = usual activities, Mental = mental 
function, Disco = discomfort and symptoms, Depr = depression, Distr = distress, Vital = vitality and Sex = 
sexual activity. *p<0.05, **p<0.01, ***p<0.001. 
 
Fig. 2. The 15D scores and profiles of SI-NET patients according to excretion. Move = mobility, See = vision, 
Hear = hearing, Breath = breathing, Sleep = sleeping, Eat = eating, Excret = excretion, Uact = usual activities, 
Mental = mental function, Disco = discomfort and symptoms, Depr = depression, Distr = distress, Vital = 
vitality and Sex = sexual activity. *p<0.05, **p<0.01, ***p<0.001. 
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Table 1. Clinical characteristics of 134 SI-NET patients  
Parameter Mean±SD (min-max) or number (%) 
Gender (female (n)/male (n)) 74/60 
Age (years) 66.8±9.9 (38.9-88.4) 
Educational level  
Less than high school 31 (23.1 %) 
High school or more 103 (76.9 %) 
BMI (kg/m2) 26.1±4.8 (17.7-42.4) 
Duration of disease (months) 81±74.1 (4-468) 
Ki-67 (n=133) 3.7±3.6 (0.5-15) 
Grade (n=133)  
Grade 1 72 (54.1 %) 
Grade 2 61 (45.9 %) 
fP-CgA (nmol/l)a 14.6±33.8 (1.3-250) 
S-5HIAA (nmol/l)b 344±827.9 (24-7470) 
Creatinine (µmol/l) 81.7±23.3 (45-190) 
Metastatic or locally advanced diseasec 122 (91 %) 
Hepatic tumour load  
0% 60 (44.8 %) 
<10%     45 (33.6 %) 
10-25%    14 (10.4 %) 
25-50%    11 (8.2 %) 
>50%    4 (3.0 %) 
Flushing 42 (31 %) 
       frequency (times per week) 0.7±2.2 
Diarrhea 85 (63 %) 
       frequency (times per week) 2.0±2.6 
Primary tumour resected  126 (94 %) 
Somatostatin analog treatment 106 (79.1 %) 
Peptide receptor radionuclide therapy 36 (26.9 %) 
Interferon therapy 9 (6.7 %) 
Chemotherapyd 4 (3.0 %) 
aNormal: <3 nmol/l 
bNormal: <123 nmol/l 
cAt the time of the questionnaires 
dCarboplatin, etoposide, temozolomide, capecitabine 
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 Table 2. Linear regression analysis in SI-NET patients using the 15D total score as dependent variable  
 
Table 3. Regression analysis in SI-NET patients using the 15D total score as dependent variable  
Parameter Regression coefficient p  
(Constant) 0.825 0.000 
Age 0.001 0.327 
Gender 0.027 0.124 
Educational level 0.037 0.081 
S-5HIAA (nmol/l) 0.000 0.504 
Somatostatin analog treatment -0.009 0.727 
Peptide receptor radionuclide therapy 0.013 0.558 
Interferon 0.033 0.331 
Ki67 0.001 0.723 
Liver metastases (yes or no) -0.011 0.608 
Cardiovascular disease 
Diabetes mellitus 
0.040 
0.039 
0.057 
0.116 
Number of medications -0.019 0.000 
Emphasis in bold denotes significant p-value <0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
D
ow
nl
oa
de
d 
by
: 
U
ni
ve
rs
ity
 o
f H
el
si
nk
i  
   
   
   
   
   
   
   
   
   
   
 
12
8.
21
4.
20
8.
20
6 
- 1
0/
9/
20
18
 1
1:
17
:2
8 
AM
Ac
ce
pte
d m
an
us
cri
pt
Table 3. Clinical characteristics of patients with normal and impaired excretion (results are presented as 
mean±SD or number (%)) 
Parameter Impaired excretiona Normal excretion p 
Female (n)/male (n) 48/39 26/21 0.153 
Age (yrs) 65.9±10.24 68.4±9.20 0.987 
fP-CgA (nmol/l)b 16.3±36.5 11.4±28.5 0.423 
S-5HIAA (nmol/l)c 394.4±951.8 252.5±528.7 0.347 
Ki-67%* 3.2±3.4 4.5±3.8 0.034 
Hepatic tumour load     
0 % 39 (44.8%) 21 (44.7%)  
<10%     28 (32.2%) 17 (36.2%)  
10-25%    8 (9.2%) 6 (12.8%)  
25-50%    9 (10.3%) 2 (4.3%)  
>50%    3 (3.4%) 1 (2.1%)  
Flushing 32 (36.8%) 10 (21.3%) 0.054 
Diarrhea (times per week) 3.0±2.7 0.4±1.2 <0.001 
Defecation (times per day) 2.7±1.6 1.7±1.0 <0.001 
Somatostatin analog treatment 71 (81.6%) 35 (74.5%) 0.336 
Cardiovascular disease 48 (55.2%) 29 (61.7%) 0.469 
Diabetes 11 (12.6%) 10 (21.3%) 0.222 
Depression 8 (9.2%) 4 (8.5%) 0.880 
Number of medications 4.9±3.3 3.5±2.1 0.003 
aSingle dimension score for excretion in 15D ≤0.8 
bNormal: <3 nmol/l 
cNormal: <123 nmol/l 
Emphasis in bold is significant p-value <0.05. 
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Table 4. SF-36 according to excretion 
  Impaired excretiona Normal excretion p 
Physical functioning 74.8±23.9 84.0±17.6 0.012 
Role limitations due to physical health 55.6±41.8 79.9±33.6 0.000 
Role limitations due to emotional problems 63.9±39.8 83.3±30.4 0.002 
Vitality 58.2±20.1 72.1±20.9 0.000 
Mental Health 76.0±15.8 81.8±17.9 0.056 
Social functioning 73.5±25.5 90.7±16.6 0.000 
Bodily pain 67.4±26.4 82.3±19.4 0.001 
General health 49.9±19.7 64.0±19.3 0.000 
aSingle dimension score for excretion in 15D ≤0.8 
Emphasis in bold is significant p-value <0.05. 
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QUALITY OF LIFE QUESTIONNAIRE (15D©) 
 
 
Please read through all the alternative responses to each question before placing a cross (x) 
against the alternative which best describes your present health status. Continue through all 15 
questions in this manner, giving only one answer to each. 
 
 
QUESTION 1.  MOBILITY 
1 (  ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs. 
2 (  ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight           
 difficulties. 
3 (  ) I am able to walk without help indoors (with or without an appliance), but outdoors               
 and/or on stairs only with considerable difficulty or with help from others.  
4 (  ) I am able to walk indoors only with help from others.  
5 (  ) I am completely bed-ridden and unable to move about. 
 
QUESTION 2.  VISION 
1 (  ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or                 
 without glasses).  
2 (  ) I can read papers and/or TV text with slight difficulty (with or without glasses).  
3 (  ) I can read papers and/or TV text with considerable difficulty (with or without glasses). 
4 (  ) I cannot read papers or TV text either with glasses or without, but I can see enough to           
 walk about without guidance.  
5 (  ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind. 
 
QUESTION 3.  HEARING 
1 (  ) I can hear normally, i.e. normal speech (with or without a hearing aid). 
2 (  ) I hear normal speech with a little difficulty. 
3 (  ) I hear normal speech with considerable difficulty; in conversation I need voices to be             
 louder than normal. 
4 (  ) I hear even loud voices poorly; I am almost deaf. 
5 (  ) I am completely deaf. 
 
QUESTION 4.  BREATHING 
1 (  ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty. 
2 (  ) I have shortness of breath during heavy work or sports, or when walking briskly on flat           
 ground or slightly uphill. 
3 (  ) I have shortness of breath when walking on flat ground at the same speed as others my age. 
4 (  ) I get shortness of breath even after light activity, e.g. washing or dressing myself. 
5 (  ) I have breathing difficulties almost all the time, even when resting. 
 
 
 
 
 
15D©/Harri Sintonen (www.15D-instrument.net) 
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QUESTION 5.   SLEEPING 
1 (  ) I am able to sleep normally, i.e. I have no problems with sleeping. 
2 (  ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes                
 waking at night. 
3 (  ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept 
 enough. 
4 (  ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely,           
 or usually waking at night and/or too early in the morning. 
5 (  ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of                  
 sleeping pills, or staying awake most of the night.      
 
 
QUESTION 6.   EATING 
1 (  ) I am able to eat normally, i.e. with no help from others. 
2 (  ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with           
 special appliances). 
3 (  ) I need some help from another person in eating. 
4 (  ) I am unable to eat by myself at all, so I must be fed by another person. 
5 (  ) I am unable to eat at all, so I am fed either by tube or intravenously.  
 
 
QUESTION 7.  SPEECH 
1 (  ) I am able to speak normally, i.e. clearly, audibly and fluently. 
2 (  ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or                 
 changes of pitch. 
3 (  ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or            
 stammering. 
4 (  ) Most people have great difficulty understanding my speech. 
5 (  ) I can only make myself understood by gestures. 
 
 
QUESTION 8.   EXCRETION 
1 (  ) My bladder and bowel work normally and without problems. 
2 (  ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with               
 urination, or loose or hard bowels. 
3 (  ) I have marked problems with my bladder and/or bowel function, e.g. occasional                   
 'accidents', or severe constipation or diarrhea. 
4 (  ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents',           
 or need of catheterization or enemas. 
5 (  ) I have no control over my bladder and/or bowel function. 
 
 
QUESTION 9.   USUAL ACTIVITIES 
1 (  ) I am able to perform my usual activities (e.g. employment, studying, housework, free-           
 time activities) without difficulty. 
2 (  ) I am able to perform my usual activities slightly less effectively or with minor difficulty. 
3 (  ) I am able to perform my usual activities much less effectively, with considerable                   
 difficulty, or not completely. 
4 (  ) I can only manage a small proportion of my previously usual activities.  
5 (  ) I am unable to manage any of my previously usual activities. 
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QUESTION 10.  MENTAL FUNCTION 
1 (  ) I am able to think clearly and logically, and my memory functions well 
2 (  ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me.   
3 (  ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat            
 impaired. 
4 (  ) I have great difficulties in thinking clearly and logically, or my memory is seriously              
 impaired. 
5 (  ) I am permanently confused and disoriented in place and time. 
 
QUESTION 11.   DISCOMFORT AND SYMPTOMS 
1 (  )  I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
2 (  )  I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
3 (  )  I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
4 (  )  I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
5 (  )  I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
 
 
QUESTION 12.   DEPRESSION 
1 (  )  I do not feel at all sad, melancholic or depressed. 
2 (  )  I feel slightly sad, melancholic or depressed. 
3 (  )  I feel moderately sad, melancholic or depressed. 
4 (  )  I feel very sad, melancholic or depressed. 
5 (  )  I feel extremely sad, melancholic or depressed. 
 
 
QUESTION 13.   DISTRESS 
1 (  )  I do not feel at all anxious, stressed or nervous. 
2 (  )  I feel slightly anxious, stressed or nervous. 
3 (  )  I feel moderately anxious, stressed or nervous. 
4 (  )  I feel very anxious, stressed or nervous. 
5 (  )  I feel extremely anxious, stressed or nervous. 
 
 
QUESTION 14.   VITALITY 
1 (  )  I feel healthy and energetic. 
2 (  )  I feel slightly weary, tired or feeble. 
3 (  )  I feel moderately weary, tired or feeble. 
4 (  )  I feel very weary, tired or feeble, almost exhausted. 
5 (  )  I feel extremely weary, tired or feeble, totally exhausted. 
 
 
QUESTION 15.  SEXUAL ACTIVITY 
1 (  )  My state of health has no adverse effect on my sexual activity. 
2 (  )  My state of health has a slight effect on my sexual activity. 
3 (  )  My state of health has a considerable effect on my sexual activity. 
4 (  )  My state of health makes sexual activity almost impossible.  
5 (  )  My state of health makes sexual activity impossible.  
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Supplementary Quality of Life Questionnaire 
 
(To be returned with the two other questionnaires (SF-36 and 15D)) 
 
 
Name:________________________________________________ DOB: ____________________ 
 
1) Are you:  
not married _____ 
living with someone _____ 
married  _____ 
divorced _____ 
widowed _____ 
 
2) What is your education? 
Elementary school  _____ 
Vocational school  _____ 
High school _____ 
Professional education _____ 
University degree _____ 
Other ____ 
 
 
3) Current medication 
Brand name and dose:   
   
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
_______________________________________________________________________________________
___________________________________________________________________________ 
_____________________________________________________________________________________ 
 
4) When were you diagnosed with neuroendocrine tumor? Year_________ 
5) Do you have diarrhea? No____________              Yes     ___  days per week 
6) How frequent are your bowel movements? _______________ per/day 
7) Do you have flush symptoms? If yes, how often?_______________________ 
8) Do you have abdominal pain? _____________No____________ Yes     ___  times per/day   
9) Date  ____________  
10) You are welcome to give additional information or comments here: 
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